Get the Stockscreener App
7.63
0.26%
-0.02
Fulcrum Therapeutics Inc stock is traded at $7.63, with a volume of 527.27K.
It is down -0.26% in the last 24 hours and down -17.42% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$7.65
Open:
$7.55
24h Volume:
527.27K
Relative Volume:
1.02
Market Cap:
$412.72M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.8291
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-12.80%
1M Performance:
-17.42%
6M Performance:
+50.49%
1Y Performance:
+119.25%
1-Day Range:
$7.27
$7.71
1-Week Range:
$7.27
$9.47
52-Week Range:
$2.315
$10.11
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
7.63 | 414.01M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (NASDAQ: FULC) grants inducement options; 10-year, 4-year vesting - Stock Titan
How Fulcrum Therapeutics Inc. stock responds to policy changes2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityWatch List & Safe Capital Investment Plans - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.July 2025 Update & Real-Time Chart Pattern Alerts - newser.com
Will Fulcrum Therapeutics Inc. stock gain from strong economyCEO Change & High Return Trade Opportunity Guides - newser.com
Statistical indicators supporting Fulcrum Therapeutics Inc.’s strengthWeekly Stock Report & Fast Moving Stock Watchlists - newser.com
Identifying reversal signals in Fulcrum Therapeutics Inc.Quarterly Earnings Report & Technical Entry and Exit Alerts - newser.com
Is Fulcrum Therapeutics Inc. stock attractive for passive investors2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Why Fulcrum Therapeutics Inc. stock is in analyst buy zone2025 Performance Recap & Growth-Oriented Investment Plans - newser.com
Fulcrum Therapeutics (FULC) Receives Buy Rating and $20 Price Target from Stifel - GuruFocus
Why Fulcrum Therapeutics Inc. stock is rated strong buy2025 Pullback Review & Weekly Watchlist of Top Performers - fcp.pa.gov.br
Will Fulcrum Therapeutics Inc. continue its uptrendJuly 2025 Setups & High Accuracy Investment Signals - newser.com
Can Fulcrum Therapeutics Inc. stock maintain growth trajectory2025 Growth vs Value & Capital Protection Trade Alerts - fcp.pa.gov.br
Can Fulcrum Therapeutics Inc. stock resist sector downturns2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Published on: 2025-11-06 04:16:47 - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesJuly 2025 Review & Real-Time Chart Breakout Alerts - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Published on: 2025-11-06 02:38:22 - newser.com
Is Fulcrum Therapeutics Inc. stock positioned for digital transformationPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - fcp.pa.gov.br
How to build a dashboard for Fulcrum Therapeutics Inc. stockTrade Performance Summary & Verified Chart Pattern Trade Signals - newser.com
How to forecast Fulcrum Therapeutics Inc. trends using time seriesJuly 2025 Gainers & Capital Protection Trading Alerts - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockTreasury Yields & Smart Investment Allocation Insights - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Signal strength of Fulcrum Therapeutics Inc. stock in tech scannersQuarterly Trade Report & Proven Capital Preservation Methods - newser.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
How sustainable is Fulcrum Therapeutics Inc. stock dividend payoutJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chart2025 Historical Comparison & Weekly Top Gainers Trade List - newser.com
Is Fulcrum Therapeutics Inc. trending in predictive chart models2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - The Manila Times
Fulcrum Therapeutics to Present Phase 1b PIONEER Trial Data on Pociredir for Sickle Cell Disease at ASH 2025 - Quiver Quantitative
Fulcrum (NASDAQ: FULC) to present pociredir SCD data, 12 mg and 20 mg cohorts at ASH - Stock Titan
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):